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The aim of this study was to investigate the clinicopathologic characteristics of sal-like protein 4 (SALL4)-immunopositive
hepatocellular carcinoma (HCC). Solitary HCCs that were surgically treated at the University of Tokyo Hospital between
2000 and 2008 were the subject of this study. Diffuse, non-punctate nuclear immunoreactivity to SALL4 was observed
in 47 of 337 HCCs (13.9%). Compared to patients with SALL4-negative HCC, patients with SALL4-positive HCC were
younger (mean 59.2 years vs. 65.2 years), more frequently female (44.7% vs. 18.3%) and positive for hepatitis B virus
angigen (42.6% vs. 18.6%). They had much higher serum levels of alpha-fetoprotein (median 3976.5 ng/ml vs. 14.0 ng/ml)
(P < 0.001). Liver function tended to be favourable, as was shown by less indocyanine green retention at 15 minutes
(ICG15), in patients with SALL4-positive HCCs (P < 0.001). Histologically, SALL4-positive HCCs exhibited less histological
differentiation (P < 0.001) and had a higher frequency of micro- or macrovascular invasion (72.3% vs. 54.1%, P = 0.019)
and intrahepatic metastasis (34.0% vs. 19.3%, P = 0.022) than SALL4-negative HCCs. SALL4-positive HCCs were more
frequently immunoreactive for cytokeratin 19 (42.6% vs. 11.7%, P < 0.001) and EpCAM (51.1% vs. 8.3%, P < 0.001). The
log-rank test indicated short-term disease-free survival (< 1 year) of patients with SALL4-positive HCC was worse than
those with SALL4-negative HCC (P = 0.019). Multivariate analyses, however, failed to show the prognostic significance of
SALL4 immunoreactivity in HCCs. In conclusion, SALL4-immunopositive HCCs constitute a subset with characteristic
patient backgrounds and somewhat aggressive behavior, as was manifested by frequent vascular invasion and
intrahepatic metastasis. There was little prognostic significance of SALL4 immunoreactivity in HCCs.
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Liver cancer is the third leading cause of cancer mortal-
ity worldwide, and hepatocellular carcinoma (HCC) is
the most common histological type of primary liver
cancer (Ferlay et al. 2010).
Although morphological aspects of HCCs, including
histologic grades and various architectural patterns, have
been documented (Theise et al. 2010), evaluating the
molecular signatures of HCCs has turned out be a more
robust and objective method for characterising their bio-
logical behavior or prognosis (Hoshida et al. 2012). For
example, HCCs with progenitor-like phenotypes have* Correspondence: jshiba-tky@umin.ac.jp
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in any medium, provided the original work is pbeen shown to have a poor prognosis (Lee et al. 2006;
Rountree et al. 2012).
Sal-like protein 4 (SALL4) is a zinc finger transcription
factor expressed in embryonic stem cells that regulates
pluripotency and early embryonic development (Zhang
et al. 2006; Yang et al. 2008; Rao et al. 2010). Its overex-
pression has been demonstrated in several types of tumors,
including germ cell tumors, acute myeloid leukaemia,
ovarian serous carcinoma, high grade urothelial carcin-
oma, and gastric adenocarcinoma (Ma et al. 2006; Cao
et al. 2009; Miettinen et al. 2014). SALL4 is a candidate
marker for HCCs with progenitor-like phenotypes since it
is one of the key regulators of hepatic development,
expressed in murine hepatoblasts and neonatal or foetal
hepatocytes (Oikawa et al. 2009). In fact, gene expression
analyses revealed that HCCs with high levels of SALL4is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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signatures and poor prognosis (Yong et al. 2013). On the
other hand, immunohistochemical studies on SALL4 pro-
tein expression in HCC have yielded inconsistent results:
the positivity rates ranges from 0 to 85% (Miettinen et al.
2014; Yong et al. 2013; Ushiku et al. 2010; Gonzalez-
Roibon et al. 2013; Oikawa et al. 2013; Zeng et al. 2014;
Liu et al. 2014; Han et al. 2014). Characteristics of SALL4-
immunopositive HCCs remain to be determined. Some
studies have noted a poor prognosis for SALL4-positive
HCC (Yong et al. 2013; Zeng et al. 2014; Liu et al. 2014),
whereas others showed SALL4 immunoreactivity in HCC
has limited significance (Gonzalez-Roibon et al. 2013;
Oikawa et al. 2013; Han et al. 2014).
In this study, we conducted an immunohistochemical
analysis of SALL4 expression in HCCs in a large Japanese
cohort to determine the clinicopathologic significance of
SALL4 immunoreactivity in HCC.
Methods
Patient selection
Consecutive HCC patients surgically treated at Tokyo
University Hospital from January 1, 2000 to December 31,
2008 were the subject of this study. Patients who under-
went initial surgery for HCC without any non-surgical
treatment more than 3 months prior to surgery were in-
cluded. Patients who underwent transarterial therapy or
portal embolization within 3 months of surgery remained
eligible if a sufficient portion of the tumor remained vi-
able. To evaluate tumor prognosis precisely, we only in-
cluded patients with solitary HCCs, with or without
intrahepatic metastasis, and excluded patients with multi-
centric HCCs (Theise et al. 2010).
Clinical data
Clinical data, including serum data immediately before
surgery, preoperative plasma levels of tumor markers,
hepatitis viral infection status, presence or absence of
diabetes mellitus, and history of heavy drinking (80 g or
more of alcohol per day), were extracted from medical
records. Body mass index (BMI) was calculated from
height and weight on admission. Patients were consid-
ered to be positive for hepatitis B virus (HBV) or hepa-
titis C virus (HCV) if they had HBV-antigen (HBs-Ag)
or HCV-antibody (HCV-Ab), respectively.
All patients were regularly screened for recurrence
through monitoring of plasma tumor markers, ultrasonog-
raphy, and dynamic computed tomography. Recurrence
was defined as the appearance of a new lesion with radio-
logical features compatible with HCC that was confirmed
with at least two imaging modalities.
Overall survival was defined as the interval between
the date of surgery and death, whereas disease-free sur-
vival was defined as the interval between the date ofsurgery and recurrence. Patients whose surgical resec-
tion was not curative were excluded from the survival
analysis. The maximum follow-up period in this study
was 4 years. Follow-up of patients who died of non–
liver-related diseases was censored at the time of death.
Pathology
Pathology reports and all tissue slides were reviewed for all
patients. Tumor location and size, histologic grade (Theise
et al. 2010), presence or absence of micro- or macrovascu-
lar invasion, bile duct involvement, and intrahepatic me-
tastasis were re-evaluated. Background liver was evaluated
according to the METAVIR system (Bedossa and Paynard
1996) or the Nonalcoholic Steatohepatitis Clinical Re-
search Network (NASH-CRN) scoring system (Kleiner
et al. 2005). The degree of steatosis (grade 0, <5%; grade 1,
5–33%; grade 2, 34–66%; grade 3, ≥67%) was recorded in
all cases.
Immunohistochemistry
Three-micrometer thick, paraffin-embedded tissue sec-
tions from the representative areas of the tumor were sub-
jected to immunohistochemical staining with the Ventana
BechMark XT automated immunostainer (Roche). We
tested two antibodies against SALL4, clone EE30 (Santa
Cruz Biotechnology) and clone 6E (Abnova), in a pilot
study of 6 HCCs whose SALL4 mRNA expression levels
were known through microarray analyses (unpublished) (3
HCCs with high SALL4 expression and 3 HCCs with low
SALL4 expression). All 3 HCCs with high SALL4 expres-
sion showed immunoreactivity to both antibodies with
diffuse, finely granular staining in the nucleus (Figure 1a),
whereas none of the 3 HCCs with low SALL4 expression
exhibited such immunoreactivity. Clone EE30 showed
somewhat stronger immunoreactivity than clone 6E in our
staining system, and, therefore, we used clone EE30 (at
1:50 dilution) in the following analysis. As punctate immu-
noreactivity in the nucleus (Figure 1b) was observed in
both SALL4-high and SALL4-low HCCs, we did not con-
sider this staining was significant in this study.
Tumors were considered positive for SALL4, cytokeratin
19, and EpCAM, respectively, if more than 2% of the tumor
cells in each slide were immunoreactive. Two pathologists
(JS and AH) examined slides to determine positive or nega-
tive cases by an eyeball estimate, and conducted careful
counting in case of disagreement to reach a consensus.
Statistical analysis
Quantitative variables were compared using the Student’s
t test or the Mann–Whitney U test, as appropriate. Cat-
egorical variables were compared with the χ2 or Fisher’s
exact test, as appropriate. Univariate and multivariate lo-
gistic regression models were used to investigate the rela-
tionship between SALL4 immunoreactivity in HCCs and
Figure 1 SALL4-immunoreactivity in hepatocellular carcinomas. Two types of immunoreactivity are shown; diffuse intense immunoreactivity
(a) and punctate immunoreactivity (b). (bar, 50 μm).
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curves were generated using the Kaplan-Meier method
and compared using the log-rank test. To determine prog-
nostic factors, multivariate regression analysis was per-
formed using the Cox proportional hazards model for
variables with P < 0.05 in the univariate analyses. Results
were deemed statistically significant if P < 0.05. Data ana-
lysis was conducted with EZR (Kanda 2013), a graphical
user interface for R (The R Foundation for Statistical
Computing).
Ethics
All patients provided written informed consent to use of
surgical materials for the study, and the University of




There were 337 patients that met the inclusion criteria
of the study. The mean age was 64.6 years (range, 19 to
85 years). There were 263 male and 74 female patients.
Seventy-four (22.0%) and 182 (54.0%) were HBs-Ag and
HCV-Ab positive, respectively. Diabetes mellitus was
documented in 86 patients (25.5%). There were 76 pa-
tients (22.6%) with a history of heavy drinking. BMI data
were available for 172 patients. Forty patients (23.3%)
had BMI ≥ 25.
SALL4 expression in HCC
Diffuse nuclear staining was noted in 47 of 337 HCCs
(13.9%), in which 2 to 95% of tumor cells showed posi-
tive reactivity. In addition, 124 HCCs (36.8%) exhibited
at least focal punctate nuclear staining. Non-neoplastic
liver tissue did not show any reactivity.
Clinical characteristics of patients with SALL4-positive HCC
Table 1 shows the characteristics of patients with SALL4-
positive HCC. Compared to patients with SALL4-negative
HCC, they were significantly younger (mean 59.2 years vs.
65.2 years, P < 0.001), more frequently female (44.7% vs.18.3%, P < 0.001) and positive for HBs-Ag (42.6% vs.
18.6%, P < 0.001), and had a lower frequency of diabetes
mellitus (12.8% vs. 27.6%, P = 0.031). Twenty-seven per
cent (20/74) of HBV-positive HCCs were immunoreactive
for SALL4, whereas only 11 per cent (20/182) of HCV-
positive HCCs and 8 per cent (7/84) of non-viral HCCs
were immunoreactive (P = 0.001 and P = 0.002, respect-
ively). Liver function tended to be better in patients with
SALL4-positive HCC, as estimated by the lower rate of in-
docyanine green retention at 15 minutes (ICG15) (mean
10.9% vs. 15.8%, P < 0.001). Patients with SALL4-positive
HCCs were characterised by higher serum levels of alpha-
fetoprotein (AFP) (median 3976.5 ng/ml vs. 14.0 ng/ml,
P < 0.001). The background liver was less frequently
steatotic in the SALL4-positive group (19.1%vs. 35.3%,
P = 0.029).
A multivariate logistic regression analysis showed that
HBV infection was independently associated with SALL4
immunoreactivity in HCCs (Table 2).
Histologic characteristics of SALL4-positive HCCs
The histologic appearance of SALL4-positive HCCs were
variable, with no specific characteristic findings (Figure 2).
Most of the SALL4-positive HCCs (46/47 tumors = 97.8%)
were moderately to poorly differentiated (Table 3, Figure 2).
Poorly differentiated cells with amphophilic cytoplasm, in-
determinate for hepatocellular or cholangiocellular differ-
entiation morphologically, were observed frequently (27/
47 tumors = 57.4%) (Figure 2a). Small undifferentiated cells
with a high nuclear/cytoplasmic ratio were noted in 8 tu-
mors (17.0%) (Figure 2c and d). Ductule-like structures
formed by undifferentiated cells were observed in 4
tumors (8.5%) (Figure 2d). Pleomorphic large cells were
frequently observed in 6 tumors (12.8%). A sarcomatoid
component was observed in 3 tumors (6.4%). In 7 tumors
(14.9%), more than 10% of tumor cells showed fatty
changes. Clear cells were predominant, at least focally (in
1 low power field), in 24 tumors (51.1%) (Figure 2b). More
than occasional hyaline droplets (Figure 2b), Mallory-
Denk bodies, and bile duct production were observed in
28 (59.6%), 12 (25.5%), and 9 (19.1%) tumors, respectively.
Table 2 Predictors of SALL4 immunoreactivity in
hepatocellular carcinomas
Univariate analysis
Variable Odds Ratio (95% CI) P
HBV 3.240 (1.690-6.200) <0.001
HCV 0.585 (0.314-1.090) 0.091
Diabetes mellitus 0.384 (0.157-0.940) 0.036
History of alcohol intakea 0.367 (0.140-0.964) 0.041
Body mass index≥25 (kg/m2) 0.249 (0.056-1.110) 0.068
Preoperative treatmentb 0.958 (0.509-1.810) 0.895
Liver cirrhosis 1.170 (0.623-2.200) 0.626
Background Steatosisc 0.434 (0.202-0.933) 0.032
Multivariate analysis
Variable Odds Ratio (95% CI) P
HBV 3.110 (1.590-6.070) <0.001
Diabetes mellitus 0.474 (0.189-1.190) 0.112
History of alcohol intakea 0.436 (0.162-1.170) 0.099
Background steatosisc 0.437 (0.199-0.963) 0.039
HBV, hepatitis B virus; HCV, hepatitis C virus.
Significant P-values are indicated in bold.
aIntake of 80 g or more of alcohol per day.
bPreoperative treatment included transcatheter arterial embolization,
transcatheter arterial infusion chemotherapy, transcatheter arterial
chemoembolization, or portal embolization.
cSteatosis in 5% or more of hepatocytes.







Age (years, mean±SD) 59.2±13.1 65.2±10.4 <0.001
Sex (male:female) 26:21 237:53 <0.001
HBV positive 20 (42.6%) 54 (18.6%) <0.001
HCV positive 20 (42.6%) 162 (55.9%) 0.086
HBV/HCV negative 7 (14.9%) 77 (26.6%) 0.087
Diabetes mellitus (+) 6 (12.8%) 80 (27.6%) 0.031
History of alcohol
intakea (+)
5 (42.8%) 71 (24.5%) 0.038
Body mass index≥25
(kg/m2)
2/25 (8.0%)b 38/147 (25.9%)b 0.070
TP (g/dl, mean±SD) 7.05±0.50 7.13±0.59 0.356
ALB (g/dl, mean±SD) 3.74±0.44 3.74±0.42 0.996
ChE (IU/l, mean±SD) 232.1±78.9 224.7±75.7 0.536
AST (IU/l, mean±SD) 40.8±23.8 48.6±38.4 0.191
ALT (IU/l, mean±SD) 42.4±26.6 44.2±29.3 0.694
TB (mg/dl, mean±SD) 0.69±0.29 0.77±0.30 0.099
PT (%, mean±SD) 82.4±11.8 79.9±12.5 0.206
Plt (×104/μl, mean±SD) 18.8±9.2 17.7±7.2 0.379
ICG15 (%, mean±SD) 10.9±6.7 15.8±9.4 <0.001
Child-Pugh (A/B) 44/3 253/37 0.328
AFP (ng/ml, median [IQR]) 3976.5 (25580.8) 14.0 (124.5) <0.001
PIVKA2 (mAu/ml, median
[IQR])




Liver cirrhosis (no/yes) 28/19 181/105e 0.626
Steatosisd (absent/present) 38/9 185/101e 0.029
SALL4, Sal-like protein 4; HCC, hepatocellular carcinoma; HBV, hepatitis B virus;
HCV, hepatitis C virus; TP, total protein; ALB, albumin; ChE, cholinesterase; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; TB, total bilirubin;
PT, prothrombin time; Plt, platelet count; ICG15, indocyanine green retention
at 15 minutes; AFP, alpha-fetoprotein; PIVKA2, protein induced by vitamin K
absence or antagonist-II; SD, standard deviation; IQR, interquartile range.
Significant P-values are indicated in bold.
aIntake of 80 g or more of alcohol per day.
bBody mass index data were available for 172 patients.
cPreoperative treatment included transcatheter arterial embolization,
transcatheter arterial infusion chemotherapy, transcatheter arterial
chemoembolization, or portal embolization.
dSteatosis in 5% or more of hepatocytes.
eBackground liver of four patients could not be assessed.
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in 6 tumors (12.7%).
The histology of two patients was especially note-
worthy. One tumor arose in a 24-year-old male patient
with HBV-positive liver cirrhosis. Despite a relatively
small tumor size (21 mm in diameter), the patient’s
serum AFP level was extremely high (9176 ng/ml). An
infiltrative border was unusual for the thin trabeculargrowth pattern of his tumor, which was accompanied by
extramedullary haematopoiesis (Figure 2e). The other
tumor arose in a 74-year-old female patient with chronic
HCV hepatitis, whose serum AFP level had been mark-
edly elevated (5285 ng/ml). The tumor, 40 mm in diam-
eter, was composed of seemingly well-differentiated cells
with mild nuclear atypia and clear, vacuolated cytoplasm
arranged in a thin trabecular pattern, thus resembling
foetal hepatoblastoma (Figure 2f ).
Compared with SALL4-negative HCCs, SALL4-positive
HCCs were characterised by a higher frequency of mo-
derately to poorly differentiated histology (P < 0.001) and a
higher frequency of micro- or macrovascular invasion
(72.3% vs. 54.1%, P = 0.019) and intrahepatic metastasis
(34.0 vs. 19.3%, P = 0.022) (Table 3). SALL4-positive HCCs
were more frequently immunoreactive for cytokeratin 19
(42.6% vs. 11.7%, P < 0.001) and EpCAM (51.1% vs. 8.3%,
P < 0.001). SALL4-positive and cytokeratin 19-positive
areas overlapped at least focally in most of the double-
positive cases (18/20 = 90.0%). Similar overlapping areas
were observed in most of the SALL4- and EpCAM-
positive cases (23/24 = 95.8%).
Prognosis
Log-rank test revealed that patients with SALL4-positive
HCCs had worse short-term (< 1 year) disease-free survival
(Figure 3a). Long-term disease-free survival (Figure 3b) or
Figure 2 Histologic spectrum of SALL4-immunopositive hepatocellular carcinoma (HCC). (a) Poorly differentiated HCC with amphophylic
cytoplasms. Hematoxylin and eosin (H&E) stain (bar, 100 μm). (b) Poorly differentiated HCC with clear cytoplasms and intracytoplasmic hyaline
droplets. H&E stain (bar, 100 μm). (c) Poorly differentiated HCC with small, undifferentiated cells. H&E stain (bar, 100 μm). (d) Moderately
differentiated HCC with ductile-like structures. H&E stain (bar, 100 μm). (e) Infiltrative HCC with thin-trabecular growth pattern. Extramedullary
hematopoiesis is seen. H&E stain (left bar, 1 mm; right bar, 100 μm). (f) Well differentiated HCC with thin-trabecular architecture and vacuolated
cytoplasm. H&E stain (bar, 100 μm).
Shibahara et al. SpringerPlus 2014, 3:721 Page 5 of 9
http://www.springerplus.com/content/3/1/721overall survival (Figure 3c) did not differ significantly be-
tween patients with SALL4-positive and SALL4-negative
HCCs. SALL4 expression was not a significant prognosticfactor in the multivariate Cox proportional hazards regres-
sion model (Tables 4 and 5). The multivariate analyses
indicated that cytokeratin 19 was the most significant







Size (mm, mean±SD) 58.3±35.8 52.2±38.7 0.312
















EpCAM (positive/negative) 24/23 24/266 <0.001
SALL4, sal-like protein 4; HCC, hepatocellular carcinoma; SD, standerd deviation;
well, well differentiated; mod, moderately differentiated; por, poorly differentiated;
EpCAM, epithelial cell adhesion molecule.
Significant P-values are indicated in bold.
aMicrovascular and macrovascular invasion.
bInvasion to major branch of the portal and hepatic veins.
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(SALL4, cytokeratin 19 and EpCAM).
Discussion
The present study showed that approximately 14% of con-
secutive cases of surgically treated solitary HCC wereFigure 3 Survival data for HCCs. Short-term disease free survival (< 1 yea
free (b) and overall (c) survivals of SALL4-positive and –negative HCCs do nimmunopositive for SALL4. Previous immunohistochemi-
cal studies on SALL4 expression in HCC demonstrated
positivity rates ranging from 0 to 85% (Miettinen et al.
2014; Yong et al. 2013; Ushiku et al. 2010; Gonzalez-
Roibon et al. 2013; Oikawa et al. 2013; Zeng et al. 2014;
Liu et al. 2014; Han et al. 2014). There are several reasons
for these inconsistent results, including the use of different
staining methods and interpretation of staining results.
Our previous study (Ushiku et al. 2010) failed to detect
significant SALL4 immunoreactivity in any of the 60 HCC
specimens on tissue microarrays (TMAs). Considering fre-
quently focal immunoreactivity of SALL4-positive cases in
the present study, TMA might not be a suitable method.
In addition, we did not consider punctate staining, ob-
served in several cases, as a significant finding, since this
staining pattern was completely different from the intense
staining seen in hepatoid gastric carcinoma. Gonzalez-
Roibon et al. (Gonzalez-Roibon et al. 2013) observed rela-
tively high rates of SALL4-immunoreacitivity in their
series of HCCs (32/69 = 46%). However, most positive tu-
mors (30 cases) showed punctate staining, which they also
emphasized was different from the diffuse finely granular
pattern observed in germ cell tumors. Oikawa et al.
(Oikawa et al. 2013) reported the highest positive rate (17/
20 = 85%). Although the figure from their manuscript
appeared to show relatively strong background staining,
such sensitive detection may be related to the antigen
retrieval process (steam in ethylenediaminetetraaceticr) of SALL4-positve HCC is relatively unfavorable (a). Long-term disease
ot differ significantly.
Table 4 Prognostic factors of disease-free survival of hepatocellular carcinoma
Short term (<1year) disease-free survival Disease free survival
Factor Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (> 65 years vs.
0–65 years)
0.920 (0.638–1.326) 0.655 1.013 (0.773–1.330) 0.923
Sex (female vs. male) 0.969 (0.623–1.509) 0.890 0.989 (0.717–1.364) 0.947
HBV (positive vs. negative) 1.241 (0.811–1.899) 0.319 0.929 (0.666–1.295) 0.663
HCV (positive vs. negative) 1.079 (0.748–1.556) 0.686 1.148 (0.875–1.505) 0.320
Child-Pugh (B vs. A) 1.310 (0.773–2.221) 0.316 1.413 (0.960–2.080) 0.079
AFP (>20 ng/ml vs.
0–20 ng/ml)
1.843 (1.272–2.670) 0.001 1.272 (0.834–1.939) 0.264 1.195 (0.914–1.564) 0.193
Tumor size (>5 cm vs.
0–5 cm)
3.253 (2.229–4.746) <0.001 1.776 (1.165–2.708) 0.008 2.095 (1.599–2.746) <0.001 1.626 (1.186–2.228) 0.003
Histologic grade (por vs.
well/mod)
2.220 (1.510–3.265) <0.001 1.165 (0.741–1.831) 0.508 1.298 (0.943-1.786) 0.110
Vascular invasion (present
vs. absent)
4.465 (2.805–7.108) <0.001 2.180 (1.279–3.714) 0.004 1.907 (1.443–2.519) <0.001 1.156 (0.832–1.607) 0.387
Intrahepatic metastasis
(present vs. absent)
4.730 (3.264–6.854) <0.001 2.593 (1.689–3.981) <0.001 3.989 (2.956–5.384) <0.001 2.885 (2.030–4.099) <0.001
Background liver (LC vs.
non-LC)
1.124 (0.774–1.632) 0.540 1.357 (1.032–1.786) 0.029 1.496 (1.120-1.999) 0.006
SALL4 (positive vs. negative) 1.746 (1.088–2.801) 0.021 0.843 (0.457–1.554) 0.584 1.185 (0.801–1.753) 0.396
Cytokeratin 19 (positive vs.
negative)
2.650 (1.746-4.002) <0.001 1.832 (1.145-2.931) 0.012 1.662 (1.165–2.371) 0.005 1.606 (1.100–2.345) 0.014
EpCAM (positive vs.
negative)
1.976 (1.260–3.097) 0.003 1.330 (0.794-2.230) 0.279 1.503 (1.037–2.180) 0.031 1.133 (0.768-1.672) 0.529
HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; por, poorly differentiated; well, well differentiated;
mod, moderately differentiated; LC, liver cirrhosis; SALL4, sal-like protein 4; EpCAM, epithelial cell adhesion molecule.
Significant P-values are indicated in bold.
Table 5 Prognostic factors of overall survival of hepatocellular carcinoma
Overall survival
Factor Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age (> 65 years vs. 0–65 years) 1.474 (0.904–2.404) 0.120
Sex (female vs. male) 1.086 (0.629–1.876) 0.767
HBV (positive vs. negative) 0.809 (0.443–1.478) 0.491
HCV (positive vs. negative) 1.661 (1.014–2.722) 0.044 2.093 (1.260–3.479) 0.004
Child-Pugh (B vs. A) 1.602 (0.860–2.983) 0.138
AFP (>20 ng/ml vs. 0–20 ng/ml) 1.274 (0.797–2.036) 0.312
Tumor size (>5 cm vs. 0–5 cm) 2.350 (1.462–3.775) <0.001 1.250 (0.715–2.187) 0.434
Histologic grade (por vs. well/mod) 2.868 (1.777–4.628) <0.001 1.811 (1.045–3.136) 0.034
Vascular invasion (present vs. absent) 3.724 (2.072–6.691) <0.001 1.928 (0.983–3.780) 0.056
Intrahepatic metastasis (present vs. absent) 4.215 (2.628–6.760) <0.001 3.030 (1.737–5.286) <0.001
Background liver (LC vs. non-LC) 1.303 (0.811–2.094) 0.274
SALL4 (positive vs. negative) 1.155 (0.591–2.255) 0.674
Cytokeratin 19 (positive vs. negative) 2.722 (1.607-4.612) <0.001 1.738 (0.973-3.105) 0.062
EpCAM (positive vs. negagtive) 1.615 (0.884–2.951) 0.119
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; por, poorly differentiated;
well, well differentiated; mod, moderately differentiated; LC, liver cirrhosis; SALL4, sal-like protein 4; EpCAM, epithelial cell adhesion molecule.
Significant P-values are indicated in bold.
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Patient characteristics could also affect the results. Others
(Yong et al. 2013; Zeng et al. 2014) also showed that
SALL4-positive tumors were frequent in HBV-related
HCC. These results are plausible since HBV-related HCCs
tend to overexpress hepatic progenitor genes (Guerrieri
et al. 2013), with HBV-encoded X antigen promoting stem-
ness at least to some extent (Arzumanyan et al. 2011). Ac-
cordingly, studies on Asian HCC cohorts (Yong et al. 2013;
Oikawa et al. 2013; Zeng et al. 2014; Han et al. 2014) dem-
onstrated frequent SALL4 immunoreactivity, and studies
on Western cohorts (Miettinen et al. 2014; Liu et al. 2014)
found that SALL4-immunopositive HCCs were rare. The
incidence in the present study (14%) was low compared to
other Asian studies, largely due to a relatively low incidence
(22%) of HBV-positive patients, which reflects the unique
demographics of Japanese HCC patients (Ikai et al. 2007).
Younger age and lower frequency of diabetes mellitus
in patients with SALL4-positive HCC may be associated
with the higher prevalence of an HBV-positive back-
ground, since HBV-positive patients in this study
showed these trends (data not shown). We could not
discern any reasons for a higher frequency of female pa-
tients in SALL4-positive HCCs.
An extremely high level of serum AFP was another
characteristic of SALL4-positive HCCs. This result was
consistent with previous studies (Yong et al. 2013; Zeng
et al. 2014), and may reflect progenitor-like features in
this group. Poorly differentiated histology and aggressive
behavior of SALL4-positive HCCs observed in this study,
manifested by frequent vascular invasion and intrahe-
patic metastasis, are also consistent with known charac-
teristics of HCCs with progenitor-like phenotypes (Lee
et al. 2006; Rountree et al. 2012). Extramedullary haem-
atopoiesis and hepatoblastoma-like morphology, which
were each observed in one SALL4-positive HCC, were
noteworthy in this context.
Zeng et al. (Zeng et al. 2014) observed that activation of
SALL4 induced up-regulation of hepatic stem cell markers,
including KRT19 and EpCAM, in a cell line study. Fre-
quent expression of cytokeratin 19 and EpCAM in SALL4-
immunopostive HCCs, therefore, is plausible. These
progenitor markers, however, were not always co-
expressed. This may be due to the sensitivity of the immu-
nohistochemistry technique, but it may also suggest that
diverse mechanisms contribute to the manifestation of
progenitor phenotypes in HCC. In fact, recent studies
have revealed complex mechanisms are involved in stem-
ness regulation in HCC (Oishi et al. 2014).
Despite poorly differentiated histology and aggressive
behavior, SALL4-positive HCCs exhibited worse progno-
sis only in the univariate analysis of short-term survival
in the present study. We surmised that the relativelyfavourable background liver function of patients with
SALL4-positive HCCs, as evidenced by significantly lower
ICG15 levels, modulated the results, since the state of the
background liver is a significant prognostic factor in HCC
patients, especially with regards to long-term survival
(Hoshida et al. 2008; Wu et al. 2009).
In the present study, we considered only diffuse nuclear
staining significant based on our pilot study findings. Al-
though SALL4-positive HCC based on this definition is
associated with notable clinicopathologic characteristics
not seen in HCCs with punctate immunoreactivity, even
when stratified by the extent of the positive area (data not
shown), the relationship between punctate staining and
actual protein expression levels should be fully investi-
gated. The issue is important because peptide therapy tar-
geting SALL4 is under development (Yong et al. 2013)
and immunohistochemistry might be applicable to select-
ing SALL4-overexpressing HCCs.
Conclusions
We showed that SALL4-immunopositve HCCs arose
more frequently in an HBV-positive background, exhib-
ited less histological differentiation, and had more fre-
quent vascular invasion and intrahepatic metastasis than
SALL4-negative HCCs. SALL4 expression was not a sig-
nificant prognostic factor in the multivariate Cox pro-
portional hazards regression model.
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